Previous 10 |
NEW YORK, NY, April 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“...
Mandate includes Advisory, Capital Raising and Uplisting Guidance MIAMI, FL / ACCESSWIRE / February 21, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel- based solutions to combat neuronal i...
Detailed experimental results were filed in a second provisional patent application for "Techniques for Promoting Neuronal Recovery." Preparing for animal In-vivo efficacy experiments with its QS200 ™ Candidate Product for treating Concussions and other Diffused Axonal Injuries....
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University...
NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updat...
NEW YORK, NY / ACCESSWIRE / August 14, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the filing on August 9, of a United States Provisio...